PHARMACOLOGY AND PHARMACOKINETICS OF CYCLOSPORINE

被引:50
作者
FREEMAN, DJ
机构
[1] Clinical Pharmacology Resource Group, Robarts Research Institute, London, Ont. N6A 5K8
关键词
CYCLOSPORINE; PHARMACOLOGY; PHARMACOKINETICS; METABOLISM; DRUG INTERACTIONS;
D O I
10.1016/0009-9120(91)90084-R
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Cyclosporine (CsA) is a lipophilic, immunosuppressive peptide which selectively inhibits T-lymphocyte activation in response to antigen stimulation. Although it is the drug of choice in organ transplantation, its clinical use is hampered by toxicity and unpredictable pharmacokinetics. CsA absorption from the small intestine is normally incomplete and is further reduced by intestinal dysfunction and low bile flow. That which enters the systemic blood is metabolized almost entirely by the liver and excreted in the bile. Blood CsA levels are altered to a clinically relevant degree by abnormal liver function and by drugs that induce or inhibit hepatic metabolism. Intestinal absorption may also play a role in some drug interactions. The narrow therapeutic range of CsA and the various factors that alter its kinetics underlie the continuing need to monitor this drug in blood.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 64 条
[31]  
KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054
[32]   CYCLOSPORINE METABOLISM IN HUMAN-LIVER - IDENTIFICATION OF A CYTOCHROME-P-450III GENE FAMILY AS THE MAJOR CYCLOSPORINE-METABOLIZING ENZYME EXPLAINS INTERACTIONS OF CYCLOSPORINE WITH OTHER DRUGS [J].
KRONBACH, T ;
FISCHER, V ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (06) :630-635
[33]   PROTEIN-DISULFIDE ISOMERASE AND PROLYL ISOMERASE ACT DIFFERENTLY AND INDEPENDENTLY AS CATALYSTS OF PROTEIN FOLDING [J].
LANG, K ;
SCHMID, FX .
NATURE, 1988, 331 (6155) :453-455
[34]   CATALYSIS OF PROTEIN FOLDING BY PROLYL ISOMERASE [J].
LANG, K ;
SCHMID, FX ;
FISCHER, G .
NATURE, 1987, 329 (6136) :268-270
[35]   ROLE OF LIPOPROTEINS AND ERYTHROCYTES IN THE INVITRO BINDING AND DISTRIBUTION OF CYCLOSPORIN-A IN THE BLOOD [J].
LEMAIRE, M ;
TILLEMENT, JP .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1982, 34 (11) :715-718
[36]  
LEMAIRE M, 1988, J PHARMACOL EXP THER, V244, P740
[37]  
LINDHOLM A, 1987, LANCET, V1, P1262
[38]   THE EFFECTS OF ERYTHROMYCIN IN PATIENTS TREATED WITH CYCLOSPORINE [J].
MARTELL, R ;
HEINRICHS, D ;
STILLER, CR ;
JENNER, M ;
KEOWN, PA ;
DUPRE, J .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (05) :660-661
[39]  
MAURER G, 1984, DRUG METAB DISPOS, V12, P120
[40]  
MRAZ W, 1983, TRANSPLANT P S1, V15, P210